Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoto Sassa

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Current Urology|October 12, 2019
Influence of the Body Mass Index and its Effect on Tumor Characteristics and Survival among a Population with Access to Surgical Management of Upper Tract Urothelial CarcinomaTeruo Inamoto, Naoto Sassa, Ryohei Hattori, et al.
International Journal of Clinical Oncology|November 16, 2019
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trialHiroyuki Nishiyama, Yoshiaki Yamamoto, Naoto Sassa, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|January 22, 2019
[A CASE WITH LATE RECURRENCE OF EXTRAGONADAL GERM CELL TUMOR]Aya Mori, Yasuhito Funahashi, Satoshi Inoue, et al.
Cancer Medicine|December 2, 2022
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR studyMasatoshi Eto, Toshio Takagi, Go Kimura, et al.
The Prostate|December 21, 2019
Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patientsMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2020
Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patientsYoshihiko Tomita, Katsunori Tatsugami, Noboru Nakaigawa, et al.
The Prostate|April 27, 2019
The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performanceMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 6, 2018
Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patientsMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
Clinical Genitourinary Cancer|May 30, 2020
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCCYoshihiko Tomita, Sei Naito, Naoto Sassa, et al.
Clinical Genitourinary Cancer|March 4, 2025
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 TrialsPatrizia Giannatempo, Jean-Pascal Machiels, Naoto Sassa, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Current Urology|October 12, 2019
Influence of the Body Mass Index and its Effect on Tumor Characteristics and Survival among a Population with Access to Surgical Management of Upper Tract Urothelial CarcinomaTeruo Inamoto, Naoto Sassa, Ryohei Hattori, et al.
International Journal of Clinical Oncology|November 16, 2019
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trialHiroyuki Nishiyama, Yoshiaki Yamamoto, Naoto Sassa, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|January 22, 2019
[A CASE WITH LATE RECURRENCE OF EXTRAGONADAL GERM CELL TUMOR]Aya Mori, Yasuhito Funahashi, Satoshi Inoue, et al.
Cancer Medicine|December 2, 2022
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR studyMasatoshi Eto, Toshio Takagi, Go Kimura, et al.
The Prostate|December 21, 2019
Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patientsMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2020
Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patientsYoshihiko Tomita, Katsunori Tatsugami, Noboru Nakaigawa, et al.
The Prostate|April 27, 2019
The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performanceMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 6, 2018
Integrating tertiary Gleason pattern 5 into the ISUP grading system improves prediction of biochemical recurrence in radical prostatectomy patientsMasashi Kato, Akihiro Hirakawa, Yumiko Kobayashi, et al.
Clinical Genitourinary Cancer|May 30, 2020
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCCYoshihiko Tomita, Sei Naito, Naoto Sassa, et al.
Clinical Genitourinary Cancer|March 4, 2025
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 TrialsPatrizia Giannatempo, Jean-Pascal Machiels, Naoto Sassa, et al.
Pageof 9